Lv6
1770 积分 2024-10-25 加入
Overall Survival and the Evolving Benefit-Risk Assessment for Poly (ADP-ribose) Polymerase Inhibitors in Advanced Ovarian Cancer
1天前
已完结
Reply to: Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
1天前
求助中
Decoding the End Points of Poly (ADP-ribose) Polymerase Inhibitor Trials in Ovarian Cancer
1天前
求助中
Camrelizumab plus rivoceranib versus sorafenib as first-line therapy for unresectable hepatocellular carcinoma (CARES-310): a randomised, open-label, international phase 3 study
2天前
已完结
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
27天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
27天前
已完结
Perioperative Enfortumab Vedotin and Pembrolizumab in Bladder Cancer
27天前
已完结
Efficacy and Safety of Pembrolizumab or Pembrolizumab Plus Chemotherapy vs Chemotherapy Alone for Patients With First-line, Advanced Gastric Cancer
28天前
已完结
The association between pathological complete response and prognosis of gastric or adenocarcinoma of esophagogastric junction cancer following neoadjuvant chemotherapy: A meta-analysis
28天前
已完结
Perioperative toripalimab and chemotherapy in locally advanced gastric or gastro-esophageal junction cancer: a randomized phase 2 trial
28天前
已完结
皖公网安备34019202002308
